Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Europe entities : Genmab a::S save search
Genmab Announces Submission of Japan New Drug Application (JNDA) for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Published: 2022-12-21 (Crawled : 12:20) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -5.08%
H: 5.66%
C: 3.35%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -2.9%
H: 3.1%
C: 2.91%
cd20 duobody treatment drug japan application submission
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
Published: 2022-11-03 (Crawled : 14:00) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -2.44%
H: 5.65%
C: 5.65%
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: -2.18%
H: 8.91%
C: 8.17%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -1.73%
H: 4.51%
C: 3.15%
meeting therapeutics presentation
AbbVie & Genmab EHA Data Indicate LBCL Drug Could Fill Unmet Need
Published: 2022-06-13 (Crawled : 14:20) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -4.61%
H: 5.03%
C: -1.29%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -3.39%
H: 1.07%
C: -0.39%
drug
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
Published: 2022-06-10 (Crawled : 13:00) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -4.41%
H: 3.01%
C: 0.79%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -2.85%
H: 0.0%
C: 0.0%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -5.18%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -2.34%
H: 0.0%
C: 0.0%
antibody results
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
Published: 2022-06-10 (Crawled : 13:00) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -4.41%
H: 3.01%
C: 0.79%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -2.85%
H: 0.0%
C: 0.0%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -5.18%
H: 0.0%
C: 0.0%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -2.34%
H: 0.0%
C: 0.0%
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
Published: 2022-06-10 (Crawled : 11:00) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -4.41%
H: 3.01%
C: 0.79%
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: -4.98%
H: 0.0%
C: 0.0%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -5.18%
H: 0.0%
C: 0.0%
trial therapeutics results phase 2
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
Published: 2022-02-24 (Crawled : 17:00) - biospace.com/
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: -0.93%
H: 5.16%
C: 5.16%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: -1.6%
H: 7.46%
C: 7.28%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -2.63%
H: 0.0%
C: 0.0%
tivdak cel head and neck cell carcinoma
Genmab Announces that Janssen has Received Conditional European Marketing Authorization for RYBREVANT® (amivantamab) for Patients with Advanced Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations, after Failure of Platinum-base
Published: 2021-12-13 (Crawled : 09:00) - globenewswire.com
GNMSF | $281.02 3.83% 210
|
Health Technology
|
| O: 2.8%
H: 0.02%
C: -4.98%
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: -0.08%
H: 0.0%
C: 0.0%
rybrevant europe lung cancer authorization cancer
Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Published: 2021-06-22 (Crawled : 14:15) - globenewswire.com
JNJ | News | $145.74 0.67% 0.0% 9.3M
|
Health Technology
|
| O: -0.08%
H: 0.2%
C: -0.05%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: 0.09%
H: 0.63%
C: 0.53%
treatment europe authorized als
ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting
Published: 2021-05-19 (Crawled : 00:00) - biospace.com/
ADCT | $4.76 -4.03% 0.0% 280K
|
Health Technology
|
| O: -2.09%
H: 2.14%
C: -1.07%
GMAB | $28.32 -0.74% -0.74% 240K
|
Health Technology
|
| O: 0.0%
H: 0.89%
C: 0.77%
presentation therapeutics
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.